In conclusion, this meta-analysis indicated that Rg3 may enhance response rates, improve disease control rates, prolong overall survival after chemotherapy, promote an improved quality of life, reduce the treatment-related decline in leucocyte counts, reduce VEGF expression in the peripheral blood, and increase the ratio of CD4/CD8 T cells when combined with systematic chemotherapy for NSCLC. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.